Autres langues GB Sciences, Inc.

Actions

GBLX

US3615441090

Temps Différé OTC Markets Autres places de cotation 19:18:11 29/05/2024			Varia. 5j.	Varia. 1 janv.
0,01 ^USD	-9,09%		-18,03%	+56,25%

12/02	GB Sciences, Inc. publie ses résultats pour le troisième trimestre et les neuf mois se terminant le 31 décembre 2023	CI
2023	GB Sciences, Inc. publie ses résultats pour le deuxième trimestre et le semestre clôturés le 30 septembre 2023	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	20/11
GB Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23
GB Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	14/07/23
GB Sciences, Inc. Auditor Raises 'Going Concern' Doubt	14/07/23
Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of Lethbridge	11/07/23
GB Sciences, Inc. announced a financing transaction	30/06/23
GB SCIENCES INC : Change in Directors or Principal Officers (form 8-K)	14/04/23
GB Sciences, Inc. Announces Executive Changes	14/04/23
GB SCIENCES INC : Submission of Matters to a Vote of Security Holders (form 8-K)	10/03/23
GB SCIENCES INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	03/02/23
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	03/02/23
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform	22/12/22
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform	22/12/22
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations	12/12/22
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations	12/12/22
GB SCIENCES INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	09/11/22
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	09/11/22
Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients	01/11/22
TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit	27/10/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues GB Sciences, Inc.

Actions

GBLX

US3615441090

Autres langues

Filtres